Altimmune ALT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$22.56M-15.3% | -$27.36M-18.0% | -$19.01M+16.8% | -$22.15M+10.1% | -$19.58M+19.8% | ||
| $23K-20.7% | $26K-21.2% | $27K-27.0% | $30K-50.8% | $29K-72.9% | ||
| $3.38M-15.9% | $4.94M+47.3% | $3.55M+15.5% | $3.57M-17.3% | $4.02M+10.0% | ||
| —— | —— | —— | —— | -$681K— | ||
| $218K— | $192K— | $113K— | —— | —— | ||
| $709K— | —— | —— | —— | —— | ||
| $446K+1,305% | $374K— | $524K— | -$186K— | -$37K+95.4% | ||
| -$1.19M-237% | —— | $3.95M+354% | —— | $866K-48.8% | ||
| -$2.49M-46.7% | $4.35M— | $102K+102% | -$365K-107% | -$1.7M+38.3% | ||
| -$1.62M-478% | —— | $8K+104% | $1.47M— | $428K+111% | ||
| -$20.94M-24.4% | -$19.45M-6.5% | -$11.9M+56.1% | -$19.35M-6.9% | -$16.84M-3.0% | ||
| $21K— | $1K— | —— | —— | —— | ||
| $43.29M+0.3% | $88.55M+570% | $149.32M+479% | $4.43M-80.9% | $43.14M-19.4% | ||
| $39.62M+4.2% | $9.4M-65.0% | $0-100% | $105.55M+441% | $38.04M+172% | ||
| -$3.69M+27.7% | -$79.16M— | -$149.32M— | $101.11M+2,836% | -$5.1M+87.1% | ||
| $8.74M-74.8% | $61.65M+539% | $39.52M+28,329% | $37.82M+19,003% | $34.75M+385,989% | ||
| $695K+2.5% | $25K+1,150% | $0-100% | $6K-97.5% | $678K+13.0% | ||
| —— | —— | —— | —— | $4K— | ||
| $78.47M+130% | $81.13M+704% | $39.35M+14,693% | $52.24M+113,674% | $34.12M+13,172% | ||
| -$154K-1,127% | -$44K-138% | -$86K-817% | -$45K+38.4% | $15K+288% | ||
| $53.84M+342% | —— | —— | $134M+713% | $12.18M+122% | ||
| $849K— | $515K— | $381K— | —— | —— | ||
| $870K+26.8% | $911K+11.2% | $196K-80.0% | $431K-59.7% | $686K-30.2% | ||
| $218K— | $192K— | $113K— | —— | —— | ||
| $23K-20.7% | $26K-21.2% | $27K-27.0% | $30K-50.8% | $29K-72.9% | ||
| $709K— | —— | —— | —— | —— | ||
| -$2.49M-46.7% | $4.35M— | $102K+102% | -$365K-107% | -$1.7M+38.3% | ||
| -$518K+60.1% | -$29K+91.4% | -$10K— | -$1.4M— | -$1.3M+11.8% | ||
| -$1.62M-478% | —— | $8K+104% | $1.47M— | $428K+111% | ||
| $39.62M+4.2% | $9.4M-65.0% | $0-100% | $105.55M+441% | $38.04M+172% | ||
| $89K-28.8% | $140K— | $0— | $173K— | $125K— | ||
| $70.34M— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $4K— | ||
| $177K+4.1% | —— | $121K-7.6% | —— | $170K+0.6% | ||
| —— | —— | —— | —— | $173K— | ||
| -$20.96M— | -$19.45M— | -$11.9M— | —— | —— | ||
| -$20.96M— | -$19.45M— | -$11.9M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Altimmune generate?
- Altimmune (ALT) generated -$71.6M in operating cash flow over the trailing twelve months.
- What is Altimmune's free cash flow?
- After $111.0K of capital expenditures, Altimmune's free cash flow was -$68.8M over the trailing twelve months, up 10.2% year over year.
- Where does Altimmune's cash flow data come from?
- Every line is extracted from Altimmune's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
